Vicore to host R&D Day
Thursday, March 10 at 15-17 CET (9-11 AM EST) Gothenburg, Sweden, March 4, 2022 – Vicore Pharma Holding AB (publ) ("Vicore"), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2 receptor (AT2R), will host a virtual R&D Day with a focus on its primary drug development programs and this new class of medicine, AT2R agonists (ATRAGS), on Thursday, March 10, 2022, from 15:00-17:00 CET/9-11 AM EST.The R&D Day will feature presentations from Key Opinion Leaders (KOL’s) Toby Maher, M.D. Ph.D., from the Keck School of Medicine at the University of